Author:
Niu YangYang,Han XinHao,Zeng Yuan,Nanding Abiyasi,Bai Qiang,Guo SaiNan,Hou YaLi,Yu Yan,Zhang QiuJu,Li XiaoMei
Funder
Haiyan Foundation of Harbin Medical University Cancer Hospital
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference30 articles.
1. Alassaf E, Mueller A (2020) The role of PKC in CXCL8 and CXCL10 directed prostate, breast and leukemic cancer cell migration. Eur J Pharmacol 886:173453
2. Cheng Y, Ma XL, Wei YQ, Wei XW (2019) Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochim Biophys Acta Rev Cancer 1871(2):289–312
3. David JM, Dominguez C, Hamilton DH, Palena C (2016) The IL-8/IL-8R axis: a double agent in tumor immune resistance. Vaccines 4:22
4. ErenKupik G, Altundağ K (2022) The clinicopathological characteristics of pure and mixed invasive micropapillary breast carcinomas: a single center experience. Balkan Med J 39(4):275–281
5. Fang QI, Wang X, Luo G, Yu M, Zhang X, Xu N (2017) Increased CXCL8 expression is negatively correlated with the overall survival of patients with ER-negative breast cancer. Anticancer Res 37(9):4845–4852